Prognostic Significance of Downregulated Expression of Programmed Cell Death 5 in Chondrosarcoma

被引：45

作者：

Chen, Changbao ^{[1
]}

Zhou, Hua ^{[1
]}

Xu, Lanjun ^{[2
,3
]}

Liu, Xiaoguang ^{[1
]}

Liu, Zhongjun ^{[1
]}

Ma, Dalong ^{[2
,3
]}

Chen, Yingyu ^{[2
,3
]}

Ma, Qingjun ^{[1
]}

机构：

[1] Peking Univ, Dept Orthopaed Surg, Hosp 3, Beijing 100191, Peoples R China

[2] Peking Univ, Lab Med Immunol, Sch Basic Med Sci, Beijing 100191, Peoples R China

[3] Peking Univ, Ctr Human Dis Genom, Beijing 100191, Peoples R China

来源：

JOURNAL OF SURGICAL ONCOLOGY | 2010年 / 102卷 / 07期

基金：

国家高技术研究发展计划(863计划);

关键词：

Programmed Cell Death 5; prognostic significance; chondrosarcoma; TUMOR-CELLS; APOPTOSIS; PDCD5; BONE; GENE; LEUKEMIA; OVEREXPRESSION; SARCOMA; TFAR19;

D O I：

10.1002/jso.21730

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 [肿瘤学];

摘要：

Background and Objectives: Programmed Cell Death 5 (PDCD5) is a novel apoptosis-related gene and deregulation of PDCD5 is involved in tumorigenicity. This study was designed to investigate the expression level of PDCD5 and to clarify its clinical significance in chondrosarcoma. Methods: The mRNA and protein levels of PDCD5 in chondrosarcoma and matched corresponding non-tumor tissues were evaluated by real-time PCR and Western blot. respectively. The expression of PDCD5 protein was investigated by immunohistochemistry assays in chondrosarcoma, and its association with clinicopathologic factors and overall survival was also analyzed. Results: The mRNA and protein levels of PDCD5 were significantly decreased in chondrosarcoma compared with corresponding non-tumor tissues. Low expression of PDCD5 protein was 61.8% (21/34) in chondrosarcomas, as compared 12.5% (1/8) in normal bones, as well as compared 23.5% (4/17) in benign cartilage tumors. PDCD5 expression was correlated with anatomical location and histological grade. The survival rate of patients with low-PDCD5 tumors was lower than that of patients with high-PDCD5 tumors. Multivariate analysis revealed that the downregulated expression of PDCD5 was an independent prognostic factor for overall survival. Conclusions: PDCD5 is downregulated in chondrosarcoma and might be an independent prognostic factor for overall survival of chondrosarcoma patients. J. Surg. Oncol, 2010;102:838-843. (C)2010 Wiley-Liss, Inc.

引用

页码：838 / 843

页数：6

共 29 条

[1]

Bergh P, 2001, CANCER-AM CANCER SOC, V91, P1201, DOI 10.1002/1097-0142(20010401)91:7<1201::AID-CNCR1120>3.0.CO

[2]

2-W

[3]

Bertoni F., 2002, WHO CLASSIFICATION T, P247

[4]

Recombinant human PDCD5 sensitizes chondrosarcomas to cisplatin chemotherapy in vitro and in vivo [J].

Chen, Changbao ;

Zhou, Hua ;

Xu, Lanjun ;

Xu, Dong ;

Wang, Ying ;

Zhang, Yingmei ;

Liu, Xiaoguang ;

Liu, Zhongjun ;

Ma, Dalong ;

Ma, Qingjun ;

Chen, Yingyu .

APOPTOSIS, 2010, 15 (07) :805-813

[5]

Short interfering RNA against the PDCD5 attenuates cell apoptosis and caspase-3 activity induced by Bax overexpression [J].

Chen, LN ;

Wang, Y ;

Ma, DL ;

Chen, YY .

APOPTOSIS, 2006, 11 (01) :101-111

[6]

Nuclear translocation of PDCD5 (TFAR19): an early signal for apoptosis? [J].

Chen, YY ;

Sun, RH ;

Han, WL ;

Zhang, YM ;

Song, QS ;

Di, CH ;

Ma, DL .

FEBS LETTERS, 2001, 509 (02) :191-196

[7]

The classic: A system for the surgical staging of musculoskeletal sarcoma (Reprinted from Clin Orthop, vol 153, pg 106-120, 1980) [J].

Enneking, WF ;

Spanier, SS ;

Goodman, MA .

CLINICAL ORTHOPAEDICS AND RELATED RESEARCH, 2003, (415) :4-18

[8]

EVANS HL, 1977, CANCER-AM CANCER SOC, V40, P818, DOI 10.1002/1097-0142(197708)40:2<818::AID-CNCR2820400234>3.0.CO

[9]

2-B

[10]

The clinical approach towards chondrosarcoma [J].

Gelderblom, Hans ;

Hogendoorn, Pancras C. W. ;

Dijkstra, Sander D. ;

van Rijswijk, Carla S. ;

Krol, Augustinus D. ;

Taminiau, Antonie H. M. ;

Bovee, Judith V. M. G. .

ONCOLOGIST, 2008, 13 (03) :320-329

← 1 2 3 →